Results of Operations and Financial Condition. On August 11, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18…

Chief Financial Officer — Liisa Bayko: Appointment of a new Chief Financial Officer and Treasurer.

Other Events. On July 17, 2026, the Company issued a press release announcing positive additional data from its Phase 1a SAD clinical trial of TH103 in treatment-naïve patients with nAMD. Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in vision and retinal anatomy and further supporting the potential for extended treatment durability after a standard four-dose loading regimen. The expanded Phase 1a SA…

Director — Morana Jovan-Embiricos, Ph.D.: Dr. Morana Jovan-Embiricos resigned as a director and was succeeded by Laurie Keating.

Results of Operations and Financial Condition. On May 12, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 o…

Chief Financial Officer — Matthew Gall: Matthew Gall resigned as Chief Financial Officer without a named successor.

Results of Operations and Financial Condition. On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18…

Regulation FD Disclosure. On March 9, 2026, Kalaris Therapeutics, Inc. (the “Company”) made available an updated corporate presentation that it plans to use for upcoming meetings with investors and analysts at The Leerink Partners Global Healthcare Conference and other conferences. The presentation includes updates regarding timelines for reporting data from the Company’s Phase 1b/2 multi-ascending dose clinical trial of TH103 and initiating Phase 3 clinical development of TH103, as well as o…

Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Shares and the Pre-Funded Warrants is being conducted pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the S…

Other Events. Press Release On December 17, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cash Runway Based on the Company’s current operating plans, the Company’s management expects that its cash, cash equivalents and short-term investments, together with the anticipated net proceeds from the Private Placement, will be sufficient to fun…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 17, 2025, Kalaris Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per sh…

Other Events. On December 17, 2025, the Company issued a press release announcing initial data from its Phase 1a SAD trial of TH103 in treatment-naïve patients with nAMD. The data demonstrate that TH103’s engineered molecular properties translated into clinically meaningful improvements in vision and retinal anatomy, with early signals suggesting the potential for extended treatment durability. Initial Phase 1a Data Support Molecular Hypothesis with Strong Clinical Activity The Phase 1a trial…

Results of Operations and Financial Condition. On November 12, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Sec…

Chief Financial Officer and Treasurer — Matthew Gall: The company appointed Matthew Gall as Chief Financial Officer and Treasurer, a significant leadership addition.

Results of Operations and Financial Condition. On August 13, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18…

Results of Operations and Financial Condition. On May 14, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 o…

President and Chief Executive Officer — Andrew Oxtoby: The company entered into a new employment agreement with Andrew Oxtoby, continuing his role as President and Chief Executive Officer.

Director and Chair of the Audit Committee — Leone Patterson: Leone Patterson was elected as a Class III director and appointed as the Chair of the Audit Committee.

of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in

CEO — Diana Brainard, MD: Dr. Diana Brainard resigned as CEO and director with a significant severance package.

Regulation FD Disclosure. On November 7, 2024, AlloVir and Kalaris issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation that…

Entry into a Material Definitive Agreement. Merger Agreement On November 7, 2024, AlloVir, Inc., a Delaware corporation (“AlloVir”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among AlloVir, Aurora Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of AlloVir (“Merger Sub”), and Kalaris Therapeutics, Inc. (“Kalaris”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger…

Termination of a Material Definitive Agreement. On July 1, 2024, AlloVir, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”), dated July 1, 2024 (the “Effective Date”), with BP Bay Colony LLC, a Delaware limited liability company (the “Landlord”), in connection with the termination (the “Lease Termination”) of the Lease Agreement, dated September 8, 2021, by and between the Company, as tenant, and the Landlord (the “Lease Agreement”), for certain premises…

Termination of a Material Definitive Agreement. On June 5, 2024, AlloVir, Inc. (the “Company”) entered into a Termination of Sublease Agreement (the “Sublease Termination Agreement”) with AMAG Pharmaceuticals, Inc., a Delaware corporation (the “Tenant”), in connection with the termination (the “Lease Termination”) of the Sublease Agreement, dated September 8, 2021, by and between the Company, as subtenant, and the Tenant (the “Sublease Agreement”), for the premises located at 1100 Winter Stre…

The filing describes potential cash bonus payments contingent upon a change of control transaction.